

EAST Search History (INCLUDING INTERFERENCE)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	5038	544/238 OR 544/295 OR 544/357 OR 514/252.02 OR 514/252.12 OR 514/255.05	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/10/11 07:40
L2	101	L1 AND (SODIUM ADJ CHANNEL)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/10/11 07:40
L3	32	L2 AND (AMILORIDE OR PYRAZINOYL GUANIDINE OR (PYRAZINYL ADJ GUANIDINE) OR (GUANIDINOYL ADJ PYRAZINE))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/10/11 07:41

STN SEARCH TRA NSCRIPT

10/828,329

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssapal623act

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 "Ask CAS" for self-help around the clock
 NEWS 3 New STN Analyst pricing effective March 1, 2006
 NEWS 4 CA/CAPLUS enhanced with 1900-1906 U.S. patent records
 NEWS 5 KOREAPAT updates resume
 NEWS 6 Derwent World Patents Index to be reloaded and enhanced
 NEWS 7 IPC 8 Rolled-up Core codes added to CA/CAPLUS and
 NEWS 8 USPATFULL/USPAT2
 NEWS 9 The f-term thesaurus is now available in CA/CAPLUS
 NEWS 10 INPADOC
 NEWS 11 TULSA/TULSA2 reloaded and enhanced with new search and
 NEWS 12 price changes in full-text patent databases EPPULL and PCTFULL
 NEWS 13 CHEMSAFE reloaded and enhanced
 NEWS 14 ESTRUCT enhanced with Japanese patents
 NEWS 15 Coverage of Research Disclosure reinstated in DWPI
 NEWS 16 INSPEC enhanced with 1898-1968 archive
 NEWS 17 ADISCTI Reloaded and Enhanced
 NEWS 18 CA(SM)/CAPLUS(AUS) Austrian patent law changes
 NEWS 19 CA(CAPLUS) enhanced with more pre-1907 records
 NEWS 20 CA/CAPLUS fields enhanced with simultaneous left and right
 NEWS 21 truncation
 NEWS 22 CA(SM)/CAPLUS(SM) display of CA lexicon enhanced
 NEWS 23 CAS REGISTRY(SM) no longer includes Concord 3D coordinates
 NEWS 24 CAS REGISTRY(SM) updated with amino acid codes for pyrrollysine
 NEWS 25 CEBAH-VIB classification code fields reloaded with new
 NEWS 26 classification scheme

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01P, CURRENT
 MACINTOSH VERSION IS V6.0C(ENG) AND V6.0JC(JP),
 AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS IFC8 For general information regarding STN implementation of IPC 8
 NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 08:38:06 ON 11 OCT 2006

=> FILE REG
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:38:19 ON 11 OCT 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 OCT 2006 HIGHEST RN 910095-75-9
DICTIONARY FILE UPDATES: 10 OCT 2006 HIGHEST RN 910095-75-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/reqprops.html>

=> Uploading C:\Program Files\Stnexp\Queries\SDIUM CHANNEL PYRAZINE 10828329 - #3.str



chain nodes :
 7 8 9 10 11 12 13 14

ring nodes : 5 6 16 17 18 19 20 21

chain bonds : 5-8 6-7 8-9 8-10 10-11 11-12 11-14 12-13

ring bonds : 1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21

exact/norm bonds : 6-7 8-9 8-10 10-11 11-12 11-14

exact bonds : 5-8 12-13


normalized bonds : 1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21

isolated ring systems :
 containing 1 :

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:Atom 21:Atom

L1 STRUCTURE UPLOADED


=> D L1
L1 HAS NO ANSWERS
STR



"6" RING IS
1,2 - DIAZINE

Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\SODIUM CHANNEL PYRAZINE 10828329 - #2.str



Chain nodes :
7 8 9 10 11 12 13 14

ring nodes :
1 2 3 4 5 6 16 17 18 19 20 21

chain bonds :
5-8 6-7 8-9 8-10 10-11 11-12 11-14 12-13

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21

exact/norm bonds :
6-7 8-9 8-10 10-11 11-12 11-14

exact bonds :
5-8 12-13


normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21

isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom

L2 STRUCTURE UPLOADED


=> D L2
L2 HAS NO ANSWERS
STR



"6" RING IS
1,3 - PYRAZINE

Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\SODIUM CHANNEL PYRAZINE 10828329 - #1.str



Chain nodes :
7 8 9 10 11 12 13 14

ring nodes :
1 2 3 4 5 6 16 17 18 19 20 21

chain bonds :
5-8 6-7 8-9 8-10 10-11 11-12 11-14 12-13

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21

exact/norm bonds :
6-7 8-9 8-10 10-11 11-12 11-14

exact bonds :
5-8 12-13


normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21

isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom

L3 STRUCTURE UPLOADED

=> D L3
L3 HAS NO ANSWERS



Structure attributes must be viewed using STN Express query preparation.

SEARCHED ALL THREE

=> S L1
 SAMPLE SEARCH INITIATED 08:39:25 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE
 100.08 PROCESSED 0 ITERATIONS 0 ANSWERS
 SEARCH TIME: 00.00.01
 FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH 0 TO 0
 PROJECTED ITERATIONS: 0
 PROJECTED ANSWERS: 0 TO 0
 0 TO 0
 L4 0 SEA SSS SAM L1
 => S L2
 SAMPLE SEARCH INITIATED 08:39:28 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE
 100.08 PROCESSED 3 ITERATIONS 0 ANSWERS
 SEARCH TIME: 00.00.01
 FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH 3 TO 3
 PROJECTED ITERATIONS: 163
 PROJECTED ANSWERS: 0 TO 0
 L5 0 SEA SSS SAM L2
 => S L3
 SAMPLE SEARCH INITIATED 08:39:30 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE
 100.08 PROCESSED 3 ITERATIONS 2 ANSWERS
 SEARCH TIME: 00.00.01
 FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH 3 TO 3
 PROJECTED ITERATIONS: 163
 PROJECTED ANSWERS: 124
 L6 2 SEA SSS SAM L3
 => S L1 SSS FULL
 FULL SEARCH INITIATED 08:39:52 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 12 TO ITERATE

100.08 PROCESSED 12 ITERATIONS 0 ANSWERS
 SEARCH TIME: 00.00.01
 L7 0 SEA SSS FULL L1
 => S L2 SSS FULL
 FULL SEARCH INITIATED 08:39:57 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 71 TO ITERATE
 100.08 PROCESSED 71 ITERATIONS 18 ANSWERS
 SEARCH TIME: 00.00.01
 L8 18 SEA SSS FULL L2
 => S L3 SSS FULL
 FULL SEARCH INITIATED 08:40:03 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 71 TO ITERATE
 100.08 PROCESSED 71 ITERATIONS 20 ANSWERS
 SEARCH TIME: 00.00.01
 L9 20 SEA SSS FULL L3
 => FILE CAPLUS
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST
 SINCE FILE ENTRY SESSION
 500.82 501.03
 FILE 'CAPLUS' ENTERED AT 08:40:08 ON 11 OCT 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Oct 2006 VOL 145 ISS 16
 FILE LAST UPDATED: 9 Oct 2006 (20061009/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:
<http://www.cas.org/infopolicy.html>

=> S L8 OR L9
 7 L8
 4 L9
 L10 11 L8 OR L9
 => D 1-11 IBIB ABS HITSTR

L10 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2005:346797 CAPLUS
 DOCUMENT NUMBER: 142:411366
 TITLE: Preparation of pyridazinylcarbonyl-substituted ureas used for reducing risk of infection from pathogens
 INVENTOR(S): Johnson, Michael R.; Hopkins, Samuel E.

Parion Sciences, Inc., USA
PCT Int. Appl., 218 pp.

Patent
English
4

KIND	DATE
1	1950
2	1951
3	1952
4	1953
5	1954
6	1955
7	1956
8	1957
9	1958
10	1959
11	1960
12	1961
13	1962
14	1963
15	1964
16	1965
17	1966
18	1967
19	1968
20	1969
21	1970
22	1971
23	1972
24	1973
25	1974
26	1975
27	1976
28	1977
29	1978
30	1979
31	1980
32	1981
33	1982
34	1983
35	1984
36	1985
37	1986
38	1987
39	1988
40	1989
41	1990
42	1991
43	1992
44	1993
45	1994
46	1995
47	1996
48	1997
49	1998
50	1999
51	2000
52	2001
53	2002
54	2003
55	2004
56	2005
57	2006
58	2007
59	2008
60	2009
61	2010
62	2011
63	2012
64	2013
65	2014
66	2015
67	2016
68	2017
69	2018
70	2019
71	2020
72	2021
73	2022
74	2023
75	2024
76	2025
77	2026
78	2027
79	2028
80	2029
81	2030
82	2031
83	2032
84	2033
85	2034
86	2035
87	2036
88	2037
89	2038
90	2039
91	2040
92	2041
93	2042
94	2043
95	2044
96	2045
97	2046
98	2047
99	2048
100	2049

APPLICATION NO.

AZ 2005042
AM, AT, AU, AZ

WO 2004-052696
BB, BG, BR, BW

9, H,

[illegible]

A1	20050428	AU	2004-920626	20040818
A1	20050421	US	2004-279329	20040819
A2	20050421	CA	2004-2533886	20040819
A2	20060517	EP	2004-809587	20040819
DE, DK, ES, FR, GB, GR, IT, NL, SE, PT, IE, FI, KR, MY, JP, AU, CN, CA, CH, CZ, EE, HU, IL, IN, JP, KR, NL, NO, PL, PT, SI, SK, TR, TW, UK, US	20060914	US	2005-211707	20050826
A1	20060914	US	2003-496481P	20030820

MARPAT 142:411366


II 2

= H, halo, CF₃, etc.; Y = H, OH, SH, etc.; R₁ = H, etc.; R₃₋₄ = H, alkyl, OH, alkyl, Ph, etc.] are prepared

For instance **1** is prepared in 4 steps from [4-(4-hydroxyphenyl)butyl]carbamic acid benzyl ester (preparation given), 4-bromobutyronitrile and 1-(3,5-dimino-6-chloropyrazine-2-carbonyl)-2-methylsulfonamide-**4H**. It has EC50 = 25 nM in a sodium channel blocker assay. I are useful for prophylactic treatment to one or more members of a population at risk of exposure to or already exposed to one or more airborne pathogens, either from natural sources or from intentional release of pathogens into the environment.

RL: PMC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of pyridazinylanthrone-substituted ureas used for reducing risk
 of infection from pathogens)
 845753-79-9 CABIUS
 Pyrazinecarboxamide, 3,5-diamino-N-[[4-[4-[2-[(4-amino-2-
 pyridinyl)amino]-2-oxoethoxy]cyclohexyl]butyl]amino]methoxy]-6-
 anthro- (3CL) (CA INDEX NAME)

PAGE 1-1




PAGE 1-E

 —NH_2


847200-87-7 CAPUS
Pyrazinecarboxamide, 3,5-diamino-N-[[[(4-[4-2-[(4-amino-2-
pyrimidinyl)amino]-2-oxoethoxy]phenyl]butyl]amino]iminoethyl]-6-chloro-
(9CI) (CA INDEX NAME)

PAGE 1-1




PAGE 1-E

RN 847200-90-2 CAPLUS
CN Pyrazinecarboxamide, 3,5-diamino-N-[[4-[[4-(2-[[6-amino-1H-purin-2-yl]amino]-2-oxoethoxy]phenyl]butyl]amino]iminoethyl]-6-chloro- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B



RN 847200-91-3 CAPLUS
CN Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-[[imino[[4-[[4-(2-oxo-2-(1H-purin-8-ylamino)ethoxy]phenyl]butyl]amino]methyl]- (9CI) (CA INDEX NAME)



PAGE 1-A

PAGE 1-B


-NH2

L10 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:177896 CAPLUS
DOCUMENT NUMBER: 142:280225
TITLE: Preparation of capped aminopyrazinoylguanidines as sodium channel blockers

INVENTOR(S): Johnson, Michael R.; Molino, Bruce F.; Zhang, Jianhong; Sargent, Bruce J. Parion Sciences, Inc., USA
PATENT ASSIGNMENT(S): PCT Int. Appl., 100 pp.
SOURCE: CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005018644	A1	20050303	WO 2004-052685	20040818
WO 2005018644	B1	20050512		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: BM, GH, GM, KE, LS, MW, ME, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AZ, BT, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004266704	A1	20050303	AU 2004-266704	20040818
CA 2534682	AA	20050303	CA 2004-2534682	20040818
US 2005080091	A1	20050414	US 2004-920410	20040818
US 7064129	B2	20060620		
EP 1663235	A1	20060607	EP 2004-781545	20040818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 2005234072	A1	20051020	US 2005-131262	20050518
US 2005228182	A1	20051013	US 2005-138280	20050527
US 2006052394	A1	20060309	US 2005-211422	20050826
US 2006052395	A1	20060309	US 2005-211660	20050826
US 2006205738	A1	20060914	US 2005-211707	20050826
PRIORITY APPL. INFO.:			US 2003-495725P	P 20030818
			US 2004-920410	A1 20040818
			WO 2004-US2685	W 20040818

OTHER SOURCE(S): MARPAT 142:280225




AB Title compds. [I; X = H, halo, CF3, alkyl, (substituted) Ph, etc.; Y = H, OH, SH, alkoxy, alkylthio, halo, alkyl, (substituted) aryl, etc.; R1 = H, alkyl; R2 = R7, (CH2)mOR8, (CH2)mNR9R10, (CH2)mNR10R8, etc.; m = 1-7; R3, R4 = H, alkyl, hydroxyalkyl, Ph, phenylalkyl, naphthylalkyl, pyridylalkyl, etc.; R7 = H, alkyl, (substituted) Ph, etc.; R8 = H, alkyl, 2-tetrahydrofuryl, glucuronide, etc.; R10 = H, SO2Me, COR13, CO2R13, etc.; R13 = H, R7, R10, etc.; with proviso(s), were prepared. Thus, [4-(4-hydroxyphenyl)butyl]carbamate acid benzyl ester in EtOH at 70° was treated with oxiranylmethanol over 4 h to give 4.6 [4-(4-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]phenyl)butyl]carbamate acid benzyl ester. This was hydrogenolyzed in EtOH over Pd/C to give 518 3-[3-(4-(4-aminobutyl)phenoxy)-2-hydroxypropoxy]propane-1,2-diol. The

latter was stirred with Et3N and 1-(3,5-diamino-6-chloropyrazine-2-carbonyl)-2-methylisothiourea hydroiodide in EtOH at 65° to give 361 N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-(4-[4-(3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy)phenyl]butyl)guanidine (PSA 15143). The latter showed Na channel blocking activity with EC50 = 7 nM.

847200-87-7P 847200-90-2P 847200-91-3P
 RL: PAC (Pharmacological activity); SPV (Synthetic preparation); THU (Therapeutic use); BIOD (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of aminopyrazinoylguanidines as sodium channel blockers)
 RN 847200-87-7 CAPLUS
 CN Pyrazinecarboxamide, 3,5-diamino-N-[[[4-[4-(2-(4-amino-2-pyrimidinylamino)-2-oxoethoxy)phenyl]butyl]amino]iminoethyl]-6-chloro- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B


-NH2

RN 847200-90-2 CAPLUS
 CN Pyrazinecarboxamide, 3,5-diamino-N-[[[4-[4-(2-(6-amino-1H-purin-2-yl)amino)-2-oxoethoxy]phenyl]butyl]amino]iminoethyl]-6-chloro- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B



RN 847200-91-3 CAPLUS
 CN Pyrazinecarboxamide, 3,5-diamino-N-[[[4-[4-(2-oxo-2-(1H-purin-8-ylamino)ethoxy)phenyl]butyl]amino]methyl]- (9CI) (CA INDEX NAME)



PAGE 1-A

PAGE 1-B

-NH2

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:158635 CAPLUS
 DOCUMENT NUMBER: 142:261557
 TITLE: Preparation of cyclic pyrazinoylguanidine sodium channel blockers
 INVENTOR(S): Johnson, Michael R.
 PATENT ASSIGNEE(S): Parion Sciences, Inc., USA
 SOURCE: PCT Int. Appl., 101 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016879	A2	20050224	WO 2004-052680	20040818
WO 2005016879	A3	20050602		
W:	AE, AG, AL, AM, AT, AU, A2, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,			


GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RM: BM, BH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BF, BG, CH, DE, DK, EE, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL,
 PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

AU 2004264441 A1 20050224 AU 2004-264441 20040818
 CA 2534569 AA 20050224 CA 2004-2534569 20040818
 US 2005059676 A1 20050317 US 2004-920353 20040818
 EP 1670474 A2 20060621 EP 2004-801870 20040818

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

US 2006205738 A1 20060914 US 2005-211707 20050826
 US 2006205738 A1 20060914 US 2005-495720P P 20030818
 US 2004-920410 US 2004-920410 A3 20040818
 WO 2004-US26880 W 20040818


OTHER SOURCE(S): CASREACT 142:261557; MARPAT 142:261557



AB The title compds. I [X = halo, etc.; Y = H, hydroxyl, etc.; R1 = H, alkyl;
 R2 = R7, etc.; R3, R4 = H, alkyl, etc.; R7 = (un)substituted Ph, etc],
 useful as sodium channel blockers (no data), are prepared. Thus,
 N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-[4-(1-(2-
 hydroxyethyl)piperidin-4-yl)butyl]guanidine dihydrochloride was prepared in
 a multistep process starting from 4-(piperidin-4-yl)butyric acid HCl salt.
 845753-79-9P

IT RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOD (Biological study); PREP (Preparation); USES
 (Uses)

RN (Preparation of cyclic pyrazinylguanidine sodium channel blockers)
 845753-79-9 CAPUS
 CN Pyrazinecarboxamide, 3,5-diamino-N'-[4-(4-[2-(4-amino-2-
 pyrimidinyl)amino]-2-oxoethoxy)cyclohexyl]butyl]amino]iminoethyl]-6-
 chloro- (9CI) (CA INDEX NAME)



PAGE 1-A

-NH2

L10 ANSWER 4 OF 11 CAPUS COPYRIGHT 2006 ACS on STN
 2001:63982 CAPUS
 134:115971
 TITLE: Pyrazinylguanidine derivatives as conjugates of
 sodium channel blockers and methods of using the same
 for hydrating mucosal surfaces
 Boucher, Richard C., Jr.
 University of North Carolina At Chapel Hill, USA
 PCT Int. Appl., 48 pp.
 CODEN: PIXXD2


INVENTOR(S):
 PATENT ASSIGNEE(S):
 SOURCE:
 DOCUMENT TYPE:
 LANGUAGE:
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: English

THIS IS PRIOR ART

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005773	A1	20010125	WO 2000-US19775	20000719
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, ST, SV, SZ, TD, TH, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BF, BG, CH, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, GN, GA, HA, HT, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, ST, SV, SZ, TD, TH, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BF, BG, CH, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO	20000719			
CA 2378181	AA	20010125	CA 2000-2378181	20000719
EP 1196386	AK	20020417	EP 2000-948820	20000719
AT: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
US 6475509	B1	20021105	US 2000-618978	20000719
NZ 516595	A	20030725	NZ 2000-516595	20000719
JP 2004513870	T2	20040513	JP 2001-511434	20000719
AU 774865	B2	20040708	AU 2000-62262	20000719
ZA 2002000129	A	20030407	ZA 2002-129	20020116
NO 2002000242	A	20020319	NO 2002-242	20020412
US 2002165239	A1	20021107	US 2002-121913	20020412
US 6607741	B2	20030819		
US 2002158255	A1	20030902	US 2002-121917	20020412
US 6613345	B2	20030902		
PRIORITY APPLN. INFO.:			US 1999-144479P	P 19990719

OTHER SOURCE(S): MARPAT 134:115971

US 1999-144479P P 19990719
 US 2000-618978 A 20000719
 WO 2000-US19775 W 20000719




11

Nc1nc(Cl)c(N)c(C)c1

PAGE 1-A




PAGE 1-B




PAGE 1-A

● 2 HCl




PAGE 1-B

FN	321554-68-1	CAPLUS
CN	Pyrazinecarboxamide, N,N'-[1,4-butanediylbis(iminocarbonimidoyl)]bis[3,5-diamino-6-chloro-, dihydrobromide (9CI)	(CA INDEX NAME)




● 2 HBr

RN 321554-69-2 CAPLUS
CN Pyrazinecarboxamide, N,N'-[1,6-hexanediyl]bis(aminocarbonimidoyl)]bis[3,5-diamino-6-chloro-, dihydrobromide (9CI) (CA INDEX NAME)



● 2 HBr

RN 321554-70-5 CAPLUS
CN Pyrazinecarboxamide, N,N'-[1,3-phenylene]bis(methyleneaminocarbonimidoyl)]bis[3,5-diamino-6-chloro-, dihydrobromide (9CI) (CA INDEX NAME)




● 2 HBr

PAGE 1-B

NH₂


RN 321554-71-6 CAPLUS

CN Pyrazinecarboxamide, N,N'-[1,5-pentanedilyl]bis(aminocarbonimidoyl)]bis[3,5-diamino-6-chloro-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 321554-72-7 CAPLUS
CN Pyrazinecarboxamide, N,N'-[1,5-pentanedilyl]bis(aminocarbonimidoyl)]bis[3,5-diamino-6-chloro-, dihydrobromide (9CI) (CA INDEX NAME)



● 2 HBr

RN 321554-73-8 CAPLUS
CN Pyrazinecarboxamide, N,N'-[1,4-phenylene]bis(methyleneaminocarbonimidoyl)]bis[3,5-diamino-6-chloro-, dihydrobromide (9CI) (CA INDEX NAME)





● 2 HBr

PAGE 1-A

- NH₂


IT 321554-75-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (Preparation of pyrazinoylguanidine derivs. as conjugates of sodium channel
 blockers used for hydration of mucosal surfaces)
 RN 321554-75-0 CAPLUS
 CN 7-Oxa-2,4,10,12-tetraazatrideca-2,10-dienedioic acid, 3,11-bis[(3,5-
 diamino-6-chloropyrazinyl)carbonyl]amino]-, bis(phenylmethyl) ester (9CI)
 (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L10 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:855763 CAPLUS
 DOCUMENT NUMBER: 134:29423
 TITLE: Preparation of [(quinazolinylpiperidinyl)amino]benzoat
 es and analogs as bactericides
 INVENTOR(S): Kung, Pei-Pei; Cook, Phillip Dan; Guinasso, Charles
 John
 PATENT ASSIGNEE(S): Jais Pharmaceuticals, Inc., USA
 SOURCE: U.S., 22 pp.
 CODEN: USKXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6156758	A	20001205	US 1999-391843	19990908
PRIORITY APPLN. INFO.:				
OTHER SOURCE(S):				
MARPAT 134:29423				
GI				




AB R2 (NR4)nCOZRI [I; R = (un)substituted 2-quinazolinyl; R1 = OH,
 (ar)alkoxy, arylalkoxy, etc.; R4 = H, alkyl, acyl; Z = piperidine- or
 piperazine-1,4-diyl; Z1 = (un)substituted 1,4-phenylene, -pyridine-2,5- or
 -5,2-diyl, -pyrazine-2,5-diyl; n = 0 or 1] were prepared. Thus, Me
 3-amino-5,6-dichloro-2-pyrazinecarboxylate was condensed with
 1-protected-4-aminopiperidine and the deprotected product condensed with
 4-amino-2-chloro-6,7-dimethoxyquinazoline to give title compound II. Data
 for biol. activity of I were given.

IT


RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of [(quinazolinylpiperidinyl)amino]benzoates and analogs as
 bactericides)

RN 310901-30-5 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-(aminomethyl)-6-chloro-5-(4-[6,7-
 dimethoxy-4-(1-piperazinyl)-2-quinazolinyl]-1-piperazinyl)-,
 dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl
 RN 310901-33-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-5-[4-[4-(2-aminoethyl)amino]-6,7-dimethoxy-2-quinazolinyl]-1-piperazinyl]-N-(aminomethyl)-6-chloro-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

IT 310901-41-8P 310901-46-3P
 RL: RCT (Reactant); SEP (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of [(quinazolinyl)piperidinyl]amino)benzoates and analogs as bactericides)
 RN 310901-41-8 CAPLUS
 CN 1-piperazinecarboxylic acid, 4-[2-[4-[6-amino-5-[[[(aminomethyl)amino]carbonyl]-3-chloropyrazinyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 310901-46-3 CAPLUS
 CN Carbanic acid, [2-[2-[4-[6-amino-5-[[[(aminomethyl)amino]carbonyl]-3-chloropyrazinyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13

THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1995:789190 CAPLUS
 DOCUMENT NUMBER: 123:198830
 TITLE: Preparation of amidinocarbonylpyrazines as drugs.
 INVENTOR(S): Roos, Otto; Speck, Georg; Loessel, Walter; Arndts, Dietrich
 PATENT ASSIGNEE(S): Boehringer Ingelheim KG, Germany
 SOURCE: Ger. Offen., 23 pp.
 CODEN: GMMXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4337609	A1	19950511	DE 1993-4337609	19931104
CA 2175837	AA	19950511	CA 1994-2175837	19941031
WO 9512592	A1	19950511	WO 1994-EP3580	19941031
W: AM, AU, BG, CA, CN, CZ, FI, GE, IT, JP, KR, KZ, LT, LV, NO, NZ, PL, RO, RU, SI, SK, UA, US, UZ, VN				
RM: KE, MM, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9479936	A1	19950523	AU 1994-79936	19941031
AU 950388	B2	19960430		
EP 726899	A1	19960821	EP 1994-931018	19941031
EP 726899	B1	20000119		
CN 1134151	A	19961023	CN 1994-194016	19941031
JP 09505035	T2	19970520	JP 1994-513010	19941031
AT 188965	E	20000215	AT 1994-931018	19941031
ES 2140565	T3	20000301	ES 1994-931018	19941031
ZA 9408669	A	19950704	ZA 1994-8669	19941103
GR 3033034	T3	20000831	GR 2000-400720	20000322
PRIORITY APPLN. INFO:			DE 1993-4337609	19931104
OTHER SOURCE(S):			WO 1994-EP3580	19941031
GI			MARKPAT 123:198830	

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title Comps. [I; R1 = H, (hydroxy-substituted, O-interrupted) alkyl, alkenyl, alkynyl, Ph, cycloalkyl, etc.; R2 = OI, OZ, etc.; R1R2N = O3, etc.], were prepared as inhibitors of Na+/H+ and Na+/Li+ exchange useful as antihypertensives, antischisms, mucolytics, diuretics, anticancer

agents, etc. (no data). Thus, N-(4-amino-6,7-dimethoxy-2-quinazolinyl)-N,N'-dimethyl-1,2-diaminoethane, Me 3-amino-5,6-dichloropyrazine-2-carboxylate, and Et3N were heated in Me2SO at 80° to give a residue which was stirred with guanidine hydrochloride in methanolic NaOMe to give Me 3-amino-6-chloro-5-[2-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-(N,N'-dimethyl-1,2-diaminoethyl)]pyrazine-2-carboxylate. This was refluxed in DMF and the residue was treated with HCl in EtOH to give title compound (II).

IT 167684-27-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

167684-27-7 CAPLUS
Pyrazinecarboxamide, 3-amino-5-[2-(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]ethylmethylamino-N-(aminomethyl)-6-chloro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:449413 CAPLUS
DOCUMENT NUMBER: 119:49413
TITLE: New pyrazine derivatives, their preparation and their use as ingredients in drugs


INVENTOR(S): Koeppel, Herbert; Speck, Georg; Stockhaus, Klaus
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany;
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
Patent
German

DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9304048	A1	19930304	WO 1992-EPI738	19920731
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US, RW, AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG	A1	19930218	DE 1991-4127026	19910816
DE 4127026	A1	19930218	DE 1991-4130461	19910913
DE 4130461	A1	19930318	AU 1992-23870	19920731
AU 9223870	B2	19930316		
AU 669122	B2	19960530		
EP 598770	A1	19940601	EP 1992-916697	19920731
EP 598770	B1	19971015		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, JP 06509798	T2	19941102	JP 1992-504057	19920731
NO 9400523	A	19940215	NO 1994-523	19940215

PRIORITY APPL. INFO.:


DE 1991-4127026 A 19910816
DE 1991-4130461 A 19910913
WO 1992-EPI738 A 19920731
OTHER SOURCE(S): CASREACT 119:49413; MARPAT 119:49413
GI



I


AB A process for the preparation of pyrazine derivative I where R1 = H or alkyl, R2 = functionalized alkyl moiety, R3, R5 = H and R4, R6 = H, Me, Et, Bu, benzyl was accomplished by conventional methods. E.g., reaction of 4.44 g of Me 3-amino-5,6-dichloropyrazine-2-carboxylate and 3.6 g of 2-amino-1-(2,6-dimethylphenoxy)propane with 2.2 g Et3N in 40 mL anhydrous DMF gave an intermediate pyrazinecarboxylic acid ester which underwent subsequent ammonolysis in 50 mL MeOH and 80 mL of methanolic guanidine solution and eluted on silica gel by ACOH:1-PrOH:NH3 eluent to give N-amino-3-amino-6-chloro-5-[2-(1-(2,6-dimethylphenoxy)propylamino)pyrazine-2-carboxamide-hydrochloride. The products are suitable for use as active ingredients in drugs (no data).
IT 147694-06-2P 147694-29-9P 147694-13-6P
RL: SPN (Synthetic preparation); PREP (Preparation)

147694-06-2 CAPLUS
Pyrazinecarboxamide, 3-amino-5-[4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-N-(aminomethyl)-6-chloro-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

147694-29-9 CAPLUS
Pyrazinecarboxamide, 3-amino-5-[2-(4-amino-6,7-dimethoxy-2-quinazolinyl)amino]ethylmethylamino-N-(aminomethyl)-6-chloro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 147932-13-6 CAPLUS
CN Pyrazinecarboxamide, 3-amino-N-(aminomethyl)-6-chloro-5-(4-(6,7-dimethoxy-4-quinazolinyl)-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L10 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:408831 CAPLUS
TITLE: Preparation of 2-quinidinocarbonyl-3,5-diamino-6-chloropyrazines as drugs


INVENTOR(S): Koepe, Herbert; Speck, Georg; Stockhaus, Klaus
PATENT ASSIGNEE(S): Boehringer Ingelheim KG, Germany
SOURCE: Ger. Offen., 19 pp.

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4127026	A1	19930218	DE 1991-4127026	19910816
WO 9304048	A1	19930304	WO 1992-EP1738	19920731
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US				

RM: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE, BF, BJ, CE, CG, CI, CM, GN, ML, MR, SN, TD, TG
AU 9223870 A1 19930316 19920731
AU 669122 B2 19960530 19920731
EP 598770 A1 19940601 19920731
EP 598770 B1 19971015 19920731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE
JP 06509798 T2 19941102 19920731
HU 67661 A2 19950428 19920731
CZ 280760 B6 19960417 19920731
AT 159250 E 19971115 19920731
ES 2108129 T3 19971216 19920731
RU 2124008 C1 19981227 19920731
ZA 9206132 A 19930331 19920731
NO 9400523 A 19940215 19920731
PRIORITY APPL. INFO.:
DE 1991-4127026 A 19910816
DE 1991-4130461 A 19910913
WO 1992-EP1738 A 19920731

OTHER SOURCE(S): MARPAT 119:8831
GI



I




II

AB Title compds. (I: R1 = H, alkyl; R2 = morpholino, (substituted) alkyl, 4-piperidinyl, amldino; R1R2N = (substituted) piperidinyl, piperazinyl; R3-R6 = H, alkyl, PhCH2), effective inhibitors of Na+/H+ and Na+/Li+ exchange useful as antihypertensives, mucolytics, diuretics, neoplasm inhibitors, and platelet activating factor antagonists (no data), are prepared. Thus, Me 3-amino-5,6-dichloropyrazine-2-carboxylate, 2-amino-1-(2,6-dimethylphenoxy)propane, and Et3N were heated in DMF at 95-100° for 1.5 h to give Me 3-amino-6-chloro-5-(2-[1-(2,6-dimethylphenoxy)]propylamino)pyrazine-2-carboxylate. This was heated with guanidine in MeOH to give title compound II.

IT 147894-06-2P 147894-29-9P 147932-13-6P


RL: BMC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses) (Preparation of, as drug)

RN 147894-06-2 CAPLUS
CN Pyrazinecarboxamide, 3-amino-5-(4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl)-N-(aminomethyl)-6-chloro-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 147894-29-9 CAPLUS
CN Pyrazinecarboxamide, 3-amino-5-[(2-[(4-amino-6,7-dimethoxy-2-pyrazinyl)amino]ethyl)amino]-N-(aminomethyl)-6-chloro-2-dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 147932-13-6 CAPLUS
CN Pyrazinecarboxamide, 3-amino-N-(aminomethyl)-6-chloro-5-[(4-(6,7-dimethoxy-2-pyrazinyl)-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 147932-29-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-5-[(4-(4-amino-6,7-dimethoxy-2-pyrazinyl)-1-piperazinyl)-N-(aminomethyl)-6-chloro- (9CI) (CA INDEX NAME)



L10 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1967:37949 CAPLUS
DOCUMENT NUMBER: 66:37949
TITLE: Pyrazinoylguanidines
PATENT ASSIGNEE(S): Merck and Co., Inc.
SOURCE: Meth. Appl., 17 pp.
CODEN: NAXXAN
DOCUMENT TYPE: Patent
LANGUAGE: Dutch
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 6504569		19661010	NL 1965-4569	19650409
FR 1478232			FR	
FR 4498			FR	

OTHER SOURCE(S):

MARKPAT 66:37949

GI For diagram(s), see printed CA issue.

AB The title compds. I (X = halogen; R1-4 = H or alkyl) are prepared by

reaction of 3-(NR2-substituted)-6-(X-substituted)-pyrazine-2-carboxylic

acid esters (II) with guanidines H2NC-(NR2)NR2R4 (III). Thus, through

1.5 g. 3-(methylamino)-pyrazine-2-carboxylic acid in 250 ml. MeOH was

passed HCl gas, the solution evaporated, neutralized with NaHCO3 solution,

treated

with 0.5 cc. Br, and filtered to obtain 1.7 g. Me ester of

3-(methylamino)-6-bromopyrazine-2-carboxylic acid (IV), m.

181.5-3.5 (iso-PrOH). Na (0.69 g.) was dissolved in 90 ml. MeOH; to

the cold solution 3.01 g. dry powdered guanidine-HCl was added and the mixture

refluxed 30 min. and filtered; to the filtrate 2 g. IV was added to give

1.1 g. [3-(methylamino)-6-bromo-2-pyrazinyl]-guanidine, m.

230.5-1.5°. To 23 g. Me ester of 3-amino-6-bromopyrazine-2-

carboxylic acid in 40 cc. AcOH and 114 cc. 48% HBr at 5-10° a solution

of 15 cc. Br in 40 cc. AcOH was added and the mixture treated at 0-5°

with 17.4 g. NaNO2 in 30 cc. H2O in 1.5 hrs. To this stirred mixture at

20° 200 ml. 10N NaOH and saturated NaHSO3 solution was added to give 17.4

g. Me ester of 3,6-dibromopyrazine-2-carboxylic acid (V), m. 66-8°

(aqueous EtOH). V (6 g.) and piperidine 30 min. at 25° gave the

3-piperidino derivative of V, m. 88-9°, its guanidine derivative m.

220-2°. Me2NH (15 g.) and 6 g. V gave the 3-Me2N derivative of V, m.

105-8°, its guanidine derivative m. 216-18°. The Me ester of

3-bromo-6-chloropyrazine-2-carboxylic acid, m. 35-6°, its

3-[2-(dimethylamino)ethylamino] derivative, m. 105-8°, its

derivative m. 221-13°. Ethylenebis[3-(3-amino-6-chloro-2-

pyrazinoyl)guanidine]-2HCl, m. 323°. Treatment of

p-amino-6-chloro-2-pyrazinoyl)guanidine with AcCl gave the


2,3-diacyetylguanidine derivative, m. 187.5-8.5°, the analogous

2,3-di-Bz derivative m. 215-17°. [TABLE OMITTED] Other I (R = R1 = H)

given in the table were prepared. The compds. are diuretics.

IT 13301-07-0P

NC(=O)NCCNC(=O)c1cc(Cl)nc(N)c1

$\text{---CH}_2\text{---CH}_2\text{---NH---C(=O)---NH---C(=O)---}$

 2-CL
 4-NH₂
 6-CN
 (THE INDEPENDENT CL.)
 NOT QUANTITATIVELY
 PERMITTED
 IN (A) AS A
 LINKER

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 662507		19651004		
GB 1095792			GB	19631223
US 3240780		19660315	US 1963-332901	19631222
PRIORITY APPLN. INFO.:				

to dryness, saturated NaHCO_3 aqueous solution added until pH 7 is reached, and

precipitated
NaCl filtered off, 2 g. III added, and the mixture heated for a short period
and kept 1 hr. at room temperature to give 1.1 g. IV. The following compds.
are

3,6-dibromopyrazinone, 66-8%; similarly prepared (m.p. given) Me 3,6-dibromopyrazinone, 66-8%; 3-piperidino-6-bromopyrazinone, 88-90%; Me 3-dimethylamino-6-bromopyrazinone, 80-2; Me 3-bromo-6-chloropyrazinone, 35-6%; Me 3-(2-dimethylaminoethylamino)-6-chloropyrazinone, 105-8%; Me ethylamethyl[3-(3-amino-6-chloro-2-pyrazinyl)guanidine], \cdot (HCl salt m.p. 323°); 1-(3-amino-6-chloropyrazinyl)-2,3-diacetylguanidine, -; 1-(3-amino-6-chloropyrazinyl)-2,3-dibenzoylguanidine, 215-17°; 1-(3-methylamino-6-trifluoromethylpyrazinyl)-2,3-benzylguanidine, -; 1-(3-amino-6-trifluoromethylpyrazinyl)-2,3-diacetylguanidine, -; 1-(3-amino-6-trifluoromethylpyrazinyl)-2,3-dimethylguanidine, -; 1-(3-amino-6-trifluoromethylpyrazinyl)-3,3-dimethylguanidine, -; Similarly prepared were the tabulated I. (TABLE OMITTED)

13301-07-0P

NC1=NC=C(C(=O)NCCNC(=O)NCC2=NC=CC=C2)N=C1Cl

● 2 HCl

CORPORATE SOURCE: Merck & Co., Inc., West Point, PA
SOURCE: Journal of Medicinal Chemistry (1965), 8(5), 638-42
CODEN: JMCMAR, ISSN: 0022-2623

IT	9687-8-31-8, pyrazinecarboxamide, N,N'-[3-amino-6-chloro-, hydrochloride (preparation of)]
RN	9687-8-31-8 CAPLUS
CN	Pyrazinecarboxamide, N,N'-[3-amino-6-chloro-, hydrochloride (7CI) (CA INDEX NAME)]

NC1=NC=C(C(=O)NC(=O)NC(=O)NC(=O)NC(=O)NC2=NC=CC=C2N)N=C1Cl

● x HCl

=> LOG HOLD	SINCE FILE	TOTAL
COST IN U.S. DOLLARS		

\therefore NO PRIOR ART

FULL ESTIMATED COST	ENTRY	SESSION
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	56.67	557.70
CA SUBSCRIBER PRICE	SINCE FILE ENTRY -8.25	TOTAL SESSION -8.25

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 08:40:33 ON 11 OCT 2006